Fig. 3.

YARS promoted the malignant progression and was correlated with adverse prognosis in gastric cancer. For HGC-27 and AGS cells, changes of a YARS protein expressions, b cell proliferation, c apoptosis, and d migration/invasion after YARS being knocked down by siRNA. For HGC-27-derived xenograft models, e in vivo tumor growth, mice body mass changes, f xenograft size/weight and statistics were compared between HGC-27 and HGC-27-YARS groups. Overall survival (OS) and disease-free survival (DFS) of patients from g GSE22377 and h MS datasets were indicated by YARS stratifications. *p < 0.05. ns not significant